ALYREF and cancer: MYCN, a stable oncogenic transcription factor, is tightly regulated by the ubiquitin-proteasome system and partially relies on ALYREF for promoting enhanced cancer cell viability and proliferation [49], while ALYREF inhibits MYCN degradation by directly transcribing USP3 at levels necessary to facilitate tumor growth.